Literature DB >> 21304007

Post-operative radiochemotherapy in patients with gastric cancer: one department's experience of 56 patients.

M Spych1, B Serbiak, A Rychter, E Jesien-Lewandowicz, L Gottwald, J Fijuth.   

Abstract

OBJECTIVES: Prognosis in patients with locally advanced stomach cancer undergoing surgery alone is poor. High local failure rates in gastric cancer have been reported of up to 70%. When a relapse occurs, attempts at curative treatment are generally unsuccessful. A retrospective analysis was performed in order to determine whether post-operative radiochemotherapy improves treatment results in patients with locally advanced gastric cancer.
METHODS: Between November 2004 and July 2008, 56 patients with clinical Stage IB-IV cancer of the stomach underwent curative gastrectomy and adjuvant radiochemotherapy. Patients with distant metastases were excluded from the analysis. The total radiation dose was 45.0 Gy. The chemotherapy regimen comprised a 5 day cycle of 5-fluorouracil at 425 mg m(-2) and leucovorin at 20 mg m(-2). Overall survival and disease-free survival, as well as toxicity, were estimated for all patients.
RESULTS: Within the study group there were 7 (13%) local recurrences, 4 (7%) distant metastases and 8 (14%) local and distant relapses. The 2 year overall survival was 48%. A total of 19 (34%) patients developed Grade 3 gastrointestinal toxicity. There were no treatment-related deaths.
CONCLUSION: Post-operative radiochemotherapy is an effective and safe regimen in patients with curatively resected locally advanced gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21304007      PMCID: PMC3473659          DOI: 10.1259/bjr/25406515

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  25 in total

1.  Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group.

Authors:  A Cuschieri; P Fayers; J Fielding; J Craven; J Bancewicz; V Joypaul; P Cook
Journal:  Lancet       Date:  1996-04-13       Impact factor: 79.321

2.  Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapy.

Authors:  M Lise; D Nitti; A Marchet; T Sahmoud; N Duez; A Fornasiero; J G dos Santos; R Labianca; P Lasser; M Gignoux
Journal:  Ann Surg Oncol       Date:  1995-11       Impact factor: 5.344

3.  Significant prognostic factors by multivariate analysis of 3926 gastric cancer patients.

Authors:  J P Kim; Y W Kim; H K Yang; D Y Noh
Journal:  World J Surg       Date:  1994 Nov-Dec       Impact factor: 3.352

4.  Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials.

Authors:  J Hermans; J J Bonenkamp; M C Boon; A M Bunt; S Ohyama; M Sasako; C J Van de Velde
Journal:  J Clin Oncol       Date:  1993-08       Impact factor: 44.544

5.  Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients.

Authors:  J J Bonenkamp; I Songun; J Hermans; M Sasako; K Welvaart; J T Plukker; P van Elk; H Obertop; D J Gouma; C W Taat
Journal:  Lancet       Date:  1995-03-25       Impact factor: 79.321

6.  Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up.

Authors:  J Estape; J J Grau; F Lcobendas; J Curto; M Daniels; N Viñolas; C Pera
Journal:  Ann Surg       Date:  1991-03       Impact factor: 12.969

7.  Results of chemoirradiation after curative resection of locally advanced gastric cancer.

Authors:  H Bora; D Unsal; M Akmansu
Journal:  Int J Clin Pract       Date:  2004-05       Impact factor: 2.503

8.  Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study.

Authors:  J S Macdonald; T R Fleming; R F Peterson; J L Berenberg; S McClure; R A Chapman; H J Eyre; D Solanki; A B Cruz; R Gagliano
Journal:  Ann Surg Oncol       Date:  1995-11       Impact factor: 5.344

9.  The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up.

Authors:  M T Hallissey; J A Dunn; L C Ward; W H Allum
Journal:  Lancet       Date:  1994-05-28       Impact factor: 79.321

10.  Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist's view.

Authors:  D H Lim; D Y Kim; M K Kang; Y I Kim; W K Kang; C K Park; S Kim; J H Noh; J W Joh; S H Choi; T S Sohn; J S Heo; C H Park; J O Park; J E Lee; Y J Park; H R Nam; W Park; Y C Ahn; S J Huh
Journal:  Br J Cancer       Date:  2004-07-05       Impact factor: 7.640

View more
  4 in total

Review 1.  Adjuvant radiochemotherapy for gastric cancer: Should we use prognostic factors to select patients?

Authors:  Linda Agolli; Riccardo Maurizi Enrici; Mattia Falchetto Osti
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

2.  Availability and outcomes of radiotherapy in Central Poland during the 2005-2012 period - an observational study.

Authors:  Justyna Chalubinska-Fendler; Wojciech Fendler; Michal Spych; Jolanta Luniewska-Bury; Wojciech Mlynarski; Jacek Fijuth
Journal:  BMC Cancer       Date:  2015-04-02       Impact factor: 4.430

3.  Survival of gastric cancer patients based on pathologic and demographic characteristics in Mazandaran between 2007 and 2013.

Authors:  Abolfazl Nikpour; Alireza Khalilian; Iradj Maleki; Hossein Mohsenipouya; Jamshid Yazdani Charati
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2019

Review 4.  tRNA-derived fragments in gastric cancer: Biomarkers and functions.

Authors:  Maryam Kohansal; Ali Ghanbarisad; Reza Tabrizi; Abdolreza Daraei; Mojtaba Kashfi; Hailin Tang; Cailu Song; Yongming Chen
Journal:  J Cell Mol Med       Date:  2022-08-11       Impact factor: 5.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.